Try our Advanced Search for more refined results
Life Sciences - October, 2017
366 articles
- Investor Tells Of Cash-Out Woes In Trial Of Ex-Katten Atty
- Ex-Biopharma Exec Enjoined From Sharing Trade Secrets
- Walgreens Hit With Suit Over Prescription That Killed Child
- Valeant Pays $13M To End Diabetes Drug Royalty Claims
- 'Poorly Drafted' Patent Deals Can't End Janssen Suit: Judge
- Feds Seek 20 Years For Ex-ArthroCare CEO For $750M Fraud
- 5 More Companies Launch IPOs Seeking To Raise $692M
- Drugmakers Want Chicago's Opioid Suit Paused Pending MDL
- Insys Founder Resigns From Board After Opioid Charges
- Walgreens, CVS, Others Exit Lidoderm Antitrust MDL
- Deals Rumor Mill: Petrobras, SenseTime, Staples
- Without Motive, Murder Hard To Prove In Meningitis Trials
- Full Fed Circ. Asked To Review Ensnarement In $200M IP Suit
- FDA Lets 8 EU Regulators Conduct Its Drug Inspections
- J&J Calls Witness Tampering Accusation 'Overblown'
- State AGs Triple Size Of Generic Price-Fixing Litigation
- J&J Unit Hit With Trimmed FCA Suit Over Hip Implants
- NJ Sues Purdue Pharma Over Opioid Marketing
- Judging A Book: McConnell Reviews 'Unequal'
- No Basis For Personal Jurisdiction In MDL Direct Filing
- Alere Infringed Blood Analysis Patents, Suit Says
- Japan's Kirin Readies $780M Exit From Amgen Joint Venture
- Eye Drug Co. Can Relocate Shareholder Suits To Mass.
- J&J Toxicologist Defends Brand's Talc In Mesothelioma Trial
- Retrophin Privilege Fray Irks Judge At Ex-Katten Atty's Trial
- Union Sues J&J Over Alleged Remicade Monopoly Plot
- Health Care Fraudster Gets 2.5 Years For Role In $175M Plot
- Drug Developer Must Face Suboxone Product-Hopping Claims
- Par Pharma Suit Tests FDA's Drug Pricing Pushback
- Mylan Scores Costs After Win In Blood-Thinner IP Row
- Surgeon Picks Bone With J&J's DePuy Over Spinal Device
- Montel Williams Says Pot Cos. Used His Name In 'Fake News'
- PTAB Reverses Course, Institutes Review Of Herceptin Patent
- NPR Station Can Get Meningitis Juror Names, But Must Wait
- Novartis To Pick Up French Cancer Drug Co. In $3.9B Deal
- Making Pro Bono Work
- Being There: Preparing Witnesses For Depositions
- Post-Grant Proceedings As A Freedom-To-Operate Tool
- 7 Firms To Guide IPOs Exceeding $1.8B Led By Cement Giant
- FCA Decision Tracker: Continued Interpretations Of Escobar
- High Court Urged To Review State Immunity In UMass IP Row
- Merck Can't Escape Fosamax MDL, Patients Tell High Court
- Amgen 'Completely Ignoring' Biosimilar Law, Genentech Says
- Stanford's $8M Clinical Worker OT Deal Stalls On PAGA Cut
- Mylan Gets Teva's Copaxone Patent Invalidated By UK Court
- Fired GNC Manager Wins $250K Verdict In Age Bias Suit
- Bristol-Myers Dodges Revival Of Abilify FCA Suit At 6th Circ.
- Vitamin Maker Gets Trim Of 'Made In USA' Class Action
- Making Pro Bono Work: The Sidley-Exelon Partnership
- Despite Good Intentions, IPR Clashes With Hatch-Waxman
- Rejecting FTC Drug-Level Standard On Dietary Supplements
- Recipe For Legal Project Management: Look To BBQ Champs
- J&J Talc Caused Woman's Mesothelioma, Expert Tells Jury
- Eager To Run, Fla. Medical Marijuana Industry Crawls Forward
- Parent Company Escapes Suboxone Product-Hop Suit
- Medco Dodges 4th Version Of Drug Fraud FCA Suit
- Ropes & Gray DQ'd In Guardant Health's False Ad Suit
- Fed. Circ. Affirms Obviousness Of Merck Antibiotic Patent
- Bayer's Financing Needs Shift As Monsanto Price Falls $2.5B
- GSK, Teva See Bigger Issues Than Cash In $235M Award Fight
- Insurer Says Tissue Bank Not Covered For Nitrogen Death
- Trump Declares Opioid Emergency, Critics Call For Funding
- Stryker's 'Intrusive' Hip Implant Patient Survey Rejected
- Deals Rumor Mill: CVS, Weinstein Co., Evoqua Water Tech
- Gilead's Lucrative Hep C Patents Face PTAB Assault
- Defeated AndroGel User Must Pay Own Bills, AbbVie Says
- With New Scrutiny, Life Sci Startups Become Risky Targets
- Insys Founder Charged With Racketeering In Opioid Scheme
- Sanofi Says Mylan Infringing 18 Insulin Patents
- Insurer Seeks To Recoup Costs Of Implant Co. Suit At 9th Circ.
- Tax Court Flouted Regs In Medtronic Case, IRS Tells 8th Circ.
- Xytex Settles Claims Over Poorly Screened Sperm Donor
- Making Pro Bono Work: Can You Practice In Your State?
- 9th Circ. Endangers Mass Action Removal Under CAFA
- Representing Women At The Intersection Of Law And Finance
- Retrophin Ex-Chairman Says Ex-Katten Atty Not Independent
- Purdue Faces US Probe Over OxyContin Marketing
- Unilife Ch. 11 Plan Gets Interim OK, Despite Gaps
- FDA Defends Cigar Regs, Points To Consumer Misperceptions
- Supplement Cos., Execs Indicted Over Hidden Stimulants
- RI Doc Admits To Health Fraud, Opioid Kickback Scheme
- What To Watch For As US Reboots India Trade Engagement
- Second Pharmacist Convicted In Meningitis Outbreak Trial
- Deals Rumor Mill: Pfizer, Deutsche AM, Learning Care Group
- Teva, Mylan Win Toss Of Allergan Ulcer Drug Patent Suit
- Recent Disasters Highlight Drug Shortage Problem
- Belgian Biotech Ablynx Raises $200M In Upsized IPO
- Compounder Can't Duck Drug Marketing Suit, Allergan Says
- Making Pro Bono Work: Building Sponsorship Relationships
- PTAB Won't Review Japanese Co.'s Antibody Tech Patents
- House Bill Would Raise Stakes Of Congressional Inquiries
- What I Learned In My 1st Year: Be A Sponge
- Pomerantz Gets Lead Role As Juno Investor Class Certified
- J&J Talc User's Body Had Asbestos In It, Jury Hears
- Ex-Katten Atty Seeks To Chase Shkreli's Specter From Trial
- Drinker Biddle Attys Deny Pressuring Doc In Hip Implant Trial
- Eli Lilly Considers Sale Or IPO Of Animal Health Business
- Pharma Cos., States Battle Over Opioid Litigation Transfer
- Jury Hints At Racketeering Conviction In Meningitis Case
- Pharma Insider Trading Suspects Deny Using Nonpublic Info
- FDA Warning Wire: NYC's Most Expensive Restaurant
- Stanford, ThermoLife Can't Trim $1.3M Atty Fees In IP Suit
- Making Pro Bono Work: Beyond The Hurdles
- 2nd Circ. Won't Revive Mirena Injury MDL Against Bayer
- Amgen, Hospira Challenge $70M Biosimilar Judgment
- Ensnarement 101: Anatomy Of An Uncommon Patent Defense
- Stacking The Deck Against Opioid Plaintiffs
- J&J Wins Battle Against $417M Talc Award, But War Not Over
- Ex-Katten Atty Was Shkreli's Right-Hand Man, Jury Hears
- Allergan Patent Deal Is No Sham, Tribe Tells PTAB
- 'White Hats' Face Red Tape As Data Gets Deadly
- Patients Ask 7th Circ. To Revive Pfizer Testosterone Suits
- Justice Dept. Wants To Pause Pharma Insider Trading Row
- GE Wants Maine Law To Govern Asbestos Exposure Claims
- Doctors' Counsel Nab $27M In Sanofi Vaccine Antitrust Row
- TPG Picks Up Medical Device Maker Exactech In $625M Deal
- Judging A Book: Pryor Reviews 'Scalia Speaks'
- Lewis Brisbois Nabs Product Liability Trial Atty In San Diego
- 15 Minutes With Teva Pharmaceuticals' General Counsel
- The Inside Counsel Revolution
- Stockpiling Biologics Under Hatch-Waxman Protection
- J&J Wins Toss Of $417M Talc Cancer Verdict In Calif.
- Abbott Can't Escape Failure-To-Warn Claims In Depakote Suit
- Boehringer Sues Drugmakers To Block Generic Gilotrif Plans
- If J&J Talc Had Asbestos, It Could Cause Cancer, Expert Says
- Opioid Litigation Roundup: An Overview Of Major Cases
- Investor Sues McKesson Over Opioid Oversight Fines
- Dental Tech Co. Wins $6.8M In Trade Secrets Suit
- Sony-Fujifilm Feud Lands Among New ITC Probes
- Gilead Gets Hep C Drug Patent Suit Shipped To Calif.
- Ex-Katten Atty Betrayed Client, Feds Say As Trial Starts
- Meningitis Outbreak Murder Trial Sent To Jury
- Teva's Generic Bowel Drug Infringes Patent, Allergan Says
- 7 Firms To Guide IPOs Topping $2.1B As October Heats Up
- Doctors Fight Allergan's Attempt To Defeat Botox Pricing Suit
- RI Atty Can't Ditch Texas Suit Over Hernia Mesh Litigation
- Miss. High Court Tosses $2M Risperdal Verdict Against J&J
- How District Courts Treat Patent Eligibility In Life Sciences
- Fed. Circ. Won't Toss Mylan's Appeal Of Epilepsy Drug Patent
- Xarelto Users Taking First Two Trial Losses To 5th Circ.
- Fed. Circ. Won't Rethink Lymphoma, Myeloma Drug IP Revival
- Drinker Biddle DQ'd In Pa. Pharma Partnership Fight
- Taxation With Representation: Skadden, Sullivan, Wachtell
- How Arbitrators Maintain Proportionality In Discovery
- Ex-Pharmacist In NECC Meningitis Case Puts Blame On Boss
- Benefits Co. Rips Injunction Bid In $1.5B Antitrust Suit
- NJ Wants To Yank Doc's License For Overprescribing Opioids
- Ex-Katten Atty's Jury Won't Hear Of Shkreli Acquittal
- PTAB Issues 1st AIA Deadline Extension To Address Aqua
- Fed. Circ. Rules Judge Wrongly Axed Merck NuvaRing Patent
- 11th Circ. Upholds $27M Boston Scientific Pelvic Mesh Loss
- J&J's Talc Bore Harmful Asbestos, Calif. Retrial Jury Told
- Ex-Lead PTAB Judge Heads To Haug Partners
- Deals Rumor Mill: Unilever, easyJet, Sinochem
- AbbVie Must Face Suit Over Failed Shire Deal In Ill. Court
- Cancer Drug Maker Ends Stock Drop Action, For Now
- Still Difficult For Patent Holder To Use Equivalents Theory
- The Law Firm CFO's Role In The Strategic Planning Process
- Cos. Pursued By FTC Show How Not To Sell Health Products
- Judge Hesitant To Rubber-Stamp Aegerion's $36M Fraud Deal
- Bayer Seeks To End One-A-Day Labeling Class Action
- Generic-Drug Maker Faces Sanctions As Adderall Trial Closes
- NPR Station Wants Names, Addresses Of Meningitis Jurors
- Aurobindo Loses Fee Bid After Beating Mucinex Patent Suit
- Bayer, Others Sued Over Radioactive Waste Near Niagara Falls
- 3rd Circ. Revives Eyedrop Users' Action Over Dosage Size
- Mintz Levin Snags Ex-Foley IP Partner In San Diego
- Chicago Seeks Janssen Employees' Info In Opioid Suit
- Law Firms Must Transition To An Industry Sector Approach
- EU Accepts Becton Dickinson's Fixes For $24B Bard Buy
- Latham Snags Ex-Fish & Richardson Patent Atty In DC
- Sham Affidavits In Medical Product Liability: Part 2
- J&J Wins Mo. Appeal Of $72M Talc Cancer Verdict
- Shkreli Acquittal Inadmissible At Trial, Gov't Argues
- Restasis Ruling Could Be Bad Sign For Tribal Patent Pacts
- Tampering Flap Puts J&J Trial Attys Under Ethics Microscope​
- Sens. Scrutinize Murky Drug Pricing, Rebate Deals
- Boss Pushed Pharmacist To Step Up Testing Before Outbreak
- Pay Equity PAGA Suit Alleges Gender Bias At Calif. Co.
- Impax, Amneal Ink Deal To Become $1.75B Generics Giant
- FDA Warning Wire: Multiple Issues At Dialysis Co.
- Merck Gave Doctors Hawaii Trip Kickbacks, 9th Circ. Told
- Bio-Rad Asks 9th Circ. To Undo $8M Verdict For Ex-GC
- Reckitt Benckiser Dodges States' Suboxone Case
- J&J Asbestos Trial A New Front In Talc Litigation
- Judging A Book: Kozinski Reviews 'The Judge'
- Liberty Needn't Cover Client's $3M Expenses In SEC Probe
- Sen. Wants Repeal Of Opioid Law That Sunk Drug Czar Pick
- Tribal Immunity May Not Be Wonder Drug For Allergan
- Anti-Inversion Rule Down, But Not Out, With Texas Ruling
- Rep. Who Cut DEA Powers Out As Trump's Drug Czar Pick
- Sham Affidavits In Medical Product Liability: Part 1
- End-Payors, Direct Purchasers Get Cert. In Solodyn MDL
- Neutrogena Buyers Seek Class Cert. In Sunscreen Label Row
- Ex-Katten Atty Loses Bid To Nix Shkreli Conspiracy Charge
- Prevagen Memory Product Maker Fights Cert. In Ad Suit
- Gov't Scientists Tell Of Rare Outbreak As Trial Nears End
- Mo. High Court Pauses J&J Talc Cancer Trial Over Venue Row
- FDA Finding Doesn't Absolve Forest Labs, Parents Say
- Judge Hacks Away At Allergan's Restasis Patents
- Fresenius Can't Duck FCA Claims Over Hepatitis B Tests
- Janssen Defends Role As Sole Patent Owner In Remicade Suit
- PharMerica Says FCA Whistleblowers Got Info Secondhand
- Counsel In J&J 'Natural' Labeling Suit Seek $2.25M Fees
- Evolution Of A Crisis: Opioid Claims Pick Up Speed
- New Post-Recession Metrics For BigLaw Partner Success
- Understanding FDA Guidance On Connected Medical Devices
- Allergan, Generic Cos. Debate If Tribal Patent Deal Is A 'Sham'
- Actavis Generic Infringed Weight Loss Pill Patent, Judge Says
- Eliquis MDL Sees 24 Suits Trimmed Due To Forum Rule
- Fla. Denied Bid To Remove Judge In Medical Pot License Suit
- 9th Circ. Judge Balks At Blue Shield Customers' Cert. Bid
- Pfizer Takes $8.3M Interest Case Against US To 2nd Circ.
- J&J Loses Remand Fight In NJ Talc MDL
- Susman, Entwistle To Lead Valeant Insider Trading Suit
- Insulet Hit With Derivative Suit Over Lack Of Disclosure
- FDA Shuts Down Calif. Dietary Supplement Maker
- PE-Backed Biotech OptiNose Raises $120M In Upsized IPO
- UK Anti-Competitive Probe Targets South African Drugmaker
- Time To Lift Student Loan Counseling Restrictions
- Pa. Health Dept. Asks Court To Uproot Medical Pot Permit Suit
- Generic-Drug Lobby Asks 4th Circ. To Halt Md. Pricing Law
- Health Hires: Boston Scientific, Mintz Levin
- Allergan, Pfizer Unit Reach Deal Over Generic Dry-Eye Drug
- J&J Cites Jury Misconduct In Bid To Nix $417M Talc Verdict
- What To Expect As BigLaw Vet Eric Hargan Runs HHS
- 3 Places The Allergan Tribal Deal May Face Pushback
- Online Auto Seller Cargurus Leads 3 IPOs Totaling $227M
- Ex-ArthroCare CEO Can't Undo $750M Fraud Conviction
- Dimension Investor Sues To Block $151M Ultragenyx Merger
- 7th Circ. Won't Revive Payors' Depakote Suit Against Abbott
- Mass. Ruling Doesn't End NJ Eyedrops Case, 3rd Circ. Told
- CVC Capital, Tethys Close To Acquiring Sebia Majority Stake
- Amgen Defends $70M Biosimilar Verdict Against Hospira
- USPTO Rips 'Vitriolic' Attack On New Atty Fees Rule
- Pepper Hamilton Lands Ex-Saul Ewing Life Sciences Leader
- Microsoft Ruling Dooms Cymbalta Labeling Suit: 9th Circ.
- 1st Circ. Won't Rethink Ending Sarepta Securities Suit
- Trio Of Pharma Cos. Fight Post-Trial Bids In $1B Patent Row
- BPCIA At Fed. Circ.: Awaiting Guidance On Patent Dance
- Gorilla Glue Case Shows Cannabis IP Is Not Sticking
- 'Dr. Jekyll' Pharma Insider Trading Suspect Released Again
- Ex-Grant & Eisenhofer's Atty Looks To End $7M Fee Fight
- Philips, DOJ Reach Deal Over Defibrillator Missteps
- J&J Unit Says Wrong Venue Merits Toss Of $12M Mesh Award
- NuVasive Says Exec Breached Contract In Move To Alphatec
- Why You Should Consider Hyperlinking Your Next Brief
- Deals Rumor Mill: Novartis, Air Berlin, BMW
- Xarelto Internal Bleeding Suit Nixed As Time-Barred
- FDA Expert Testifies Of Unparalleled Contamination At NECC
- Cancer Center Settles Genetic Testing Licensing Breach Suit
- Buchanan Ingersoll Hires Kirkland Pharmaceuticals Litigator
- Tribe Bought Patents With Immunity Promise, Allergan Says
- Hi-Tech To Pay $40M In Sanctions In FTC Labeling Suit
- How Bristol-Myers Squibb May Transform Class Actions
- Trump Taps Greenberg Traurig Vet As Acting HHS Chief
- Ex-Katten Muchin Atty, Prosecutors Submit Revised Juror Q's
- Plaintiffs Can't Drop Cases Before Depakote Trial: Judge
- Supplement Co. Defends Tactics After Atty's Site Attacked
- Deals Rumor Mill: CeramTec, Atlantia, Helix Energy
- 3 Meningitis Pharmacy Workers Must Face FDA Fraud Claims
- FDA Warning Wire: Bush's Baked Beans, Univ. Of Michigan
- Asian-Americans Facing Challenges In The Legal Industry
- Mass. AG Runs Point As Top Trump Critic
- Pharma Rights Transfer Sinks Tax Deficiency, 3rd Circ. Told
- Allergan Ordered To Prove Tribe Patent Deal Isn't A 'Sham'
- Mistrial Declared In Case Alleging Asbestos In J&J Talcum
- Good And Bad News For Massachusetts Life Sci, Health Cos.
- What Duties Do Lead Lawyers Owe MDL Plaintiffs?
- Asbestos In J&J's Talc Caused Woman's Illness, Jury Told
- Forest Labs To Pay $4M To End Gender Bias Suit
- Amgen Sues Genentech To Shield Avastin Biosimilar
- MDL May Be On The Horizon In Opioid Litigation
- Judge Unlikely To Dismiss Ex-Katten Atty Conspiracy Count
- Pharmacist In Meningitis Trial Ignored Drug Recipe, Jury Told
- Generic Cos. Say Mass. Ruling Foils 3rd Circ. Eye Drop Case
- McCaskill Drafts Bill To Block Tribal Immunity In Patent Review
- A BigLaw Ladies' Guide To Becoming A 1st-Chair Trial Lawyer
- Collegium Infringing OxyContin Patents, Purdue Says
- Texas Justices Tackle 11th Circ.'s Discovery Rule Question
- Farmers Fight Syngenta Bid To Speed $218M Verdict Appeal
- Biotech Firm Can Arbitrate Patent Row At AAA, Chancery Says
- Strategies For Protecting Biotechnology In Brazil And China
- $60M Merck Pay-For-Delay Deal, $20M Atty Fees Approved
- Womble Carlyle Adds McCarter & English Patent Pros
- Medline Says CR Bard Copied Innovative Surgery Kit
- Pa. Gov. To Sign 'Right To Try' Unapproved Drugs Bill
- Attys Argue For 1/3 Slice Of $15M Asacol Deal Pie As Fees
- Foot Care Co. Says Rival Exploited Its IP In Online Sales
- Eli Lilly Beats Challenge To Cancer Treatment Patent
- Gov't Backs Strict FCA First-To-File Bar In Allergan Case
- Feds Re-Up Bid To Ban 5 Experts In Ex-Katten Atty's Trial
- Meningitis Pharmacist Brushed Off Concerns, Colleague Says
- NJ Sues Insys Over Opioid Drug Push, Calls Conduct 'Evil'
- Jilted Pa. Medical Marijuana Bidder Drops License Challenge
- IRS Can't Fight Facts In Transfer Pricing Suit, Medtronic Says
- 2nd Bellwether Jury Says AbbVie Owes AndroGel User $140M
- Fed. Circ. Erases Amgen Win Over Sanofi Cholesterol Drug
- Novartis, Genentech Again Beat Xolair Kickback Suit
- PharMerica Must Face State FCA Claims, Whistleblowers Say
- Insys To Pay $500K To End Mass. Opioid Marketing Claims
- Fed. Circ. Judge Recoils At Cesspool Remark In Axiron Suit
- J&J, DePuy Lose Bid To Pause FCA Ruling At 1st Circ.
- A New Strain Of Inequitable Conduct Litigation
- When Plaintiff Conduct Matters: Part 3
- 5 Tips To Ensure Proper Deposition Behavior
- Thoratec Investors' Heart Device Suit Revived By 9th Circ
- Atty's Tactic At USPTO Not Illegal, Judge Says
- End Payors Urge 4th Circ. To Revive Celebrex Antitrust Suit
- Calif. Appeals Court Revives Snoring Aid Class Action
- Consumers Sue J&J Unit Over Products' Hair Repair Claims
- Budd Larner Patent Litigator Joins Greenberg Traurig
- Greenberg Traurig Vet Gets Senate Nod For HHS Deputy
- Drug Co., Investors Win OK For $3.4M Stock Drop Deal
- Investor Seeks 'Phantom Pain' Device Co.'s Shareholder List
- Allergy Care Antitrust Case Headed Toward Trial
- AbbVie, Lilly Slam Discovery Bid In Testosterone MDL
- Feds Fight Ex-ArthroCare CEO's Bid To Nix Fraud Conviction
- Pa. Pharmacy To Pay $2.67M To Resolve FCA Allegations
- The Future Of Value-Based Care After Repeal And Replace
- When Plaintiff Conduct Matters: Part 2
- J&J Unit Fights To Save Remicade Patent At Fed. Circ.
- ACLU Sues FDA Over Access Restrictions To Abortion Pill
- Gilead To Take 9th Circ. Escobar Ruling To High Court
- 3rd-Party Release Constitutional, Millennium Labs Judge Says
- AbbVie's Marketing Of AndroGel 'Insidious,' Jury Told
- Novartis, Genentech Want 'Hopeless' Kickback Suit Tossed
- Allergan Tribal IP Transfer Sparks House Oversight Inquiry
- Fed. Circ. Looks At Early Statements In Neulasta Patent Row
- Keryx Seeks To Scrap Shareholder Stock-Drop Suit
- Billionaire Seeks To Pause Discovery In Supplement Co. Row
- Covidien Can't Stop Ethicon's Surgical Device Sales
- Chinese Lender Qudian Leads 2 IPO Launches Totaling $869M
- FDA Warning Wire: No Love For Playful Granola Labels
- Trump Admin Delays Penalties For Drug Price Overcharges
- Cephalon Slams Bid To Reinstate Pa. Opioid Marketing Suit
- Quest Tests Are Trade Secrets In Med Mal Suit, Pa. Court Says
- Vets Want DOD Docs About Radiation Exposure At Crash Site
- J&J, DePuy Ask 1st Circ. For Stay To Appeal FCA Ruling
- Hazy Outlook For Legislation Protecting Medical Cannabis
- Judging A Book: Tunheim Reviews 'Miles Lord'
- When Plaintiff Conduct Matters: Part 1
- Inversion Rule Defeat May Impair Regulatory Process
- Cher Alleges Biotech Co. Fraudulently Pushed Stock Sale
- Justices Let $3M Pelvic Mesh Verdict Against Ethicon Stand
- Justices Won't Review Calif. Co.'s Taxable Connection Case
- Ex-Katten Atty Fights To Keep 5 Experts In Shkreli Trial
- New Guidances Expand FDA Campaign On Drug Prices
- Novartis Not On Hook For Generic's Label, Calif. Justices Hear
- Valeant Launches $1B Private Bond To Restructure Debt
- PharMerica Looks To Duck Last Claims In Kickback Suit
- IP Attys Back Regeneron Over Inequitable Conduct Finding
- P&G Agrees To Pay Up To $30M To End Probiotic False Ad Suit
- Big Pharma Wants Opioid-Epidemic Class Claims Tossed
- Shire Hits Allergan With Antitrust Suit Over Dry Eye Drugs
- Feds Ask 1st Circ. To Revive Meningitis Outbreak Charges
- Technology Assisted Review Can Work For Small Cases
- GNC Hit With $20M Suit Over Supplement Co.'s Collapse
- Roche Ducks Cancer Drug Antitrust Suit
- Pharmacist In Meningitis Trial Says He Never Tried To Run
- Calif. City Can Block Tax-Delinquent Weed Shop, Panel Says
- Supreme Court Turns Down Trio Of Antitrust Appeals
- Pfizer Loses Bid To Stop Rebate Disclosures To Lawmakers
- Intuitive Surgical Can't Toss Investors' Robot Glitch Suit
- Law360 Sizes Up The Term To Come
- IRS Anti-Inversion Rule That Sank Pfizer Deal Struck Down